Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection

Author:

Baldeon Vaca Gabriela1ORCID,Meyer Michelle23ORCID,Cadete Ana1ORCID,Hsiao Chiaowen Joyce1ORCID,Golding Anne1,Jeon Albert1,Jacquinet Eric1,Azcue Emily1ORCID,Guan Chenxia Monica1,Sanchez-Felix Xavier1,Pietzsch Colette A.23ORCID,Mire Chad E.23ORCID,Hyde Matthew A.23ORCID,Comeaux Margaret E.23ORCID,Williams Julie M.23,Sung Jean C.1,Carfi Andrea1,Edwards Darin K.1,Bukreyev Alexander234ORCID,Bahl Kapil1ORCID

Affiliation:

1. Moderna Inc., Cambridge, MA, USA.

2. Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA.

3. Galveston National Laboratory, Galveston, TX, USA.

4. Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.

Abstract

Intranasal vaccination represents a promising approach for preventing disease caused by respiratory pathogens by eliciting a mucosal immune response in the respiratory tract that may act as an early barrier to infection and transmission. This study investigated immunogenicity and protective efficacy of intranasally administered messenger RNA (mRNA)–lipid nanoparticle (LNP) encapsulated vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Syrian golden hamsters. Intranasal mRNA-LNP vaccination systemically induced spike-specific binding [immunoglobulin G (IgG) and IgA] and neutralizing antibodies. Intranasally vaccinated hamsters also had decreased viral loads in the respiratory tract, reduced lung pathology, and prevented weight loss after SARS-CoV-2 challenge. Together, this study demonstrates successful immunogenicity and protection against respiratory viral infection by an intranasally administered mRNA-LNP vaccine.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference51 articles.

1. World Health Organization The top 10 causes of death (2020); www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.

2. World Health Organization COVID-19 vaccine tracker and landscape (2022); www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.

3. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

4. Emerging infectious diseases and pandemic potential: status quo and reducing risk of global spread

5. Ten great public health achievements--worldwide, 2001–2010;Centers for Disease Control and Prevention (CDC);MMWR Morb. Mortal. Wkly Rep.,2011

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3